PA8603801A1 - Derivados de la quinazolina - Google Patents
Derivados de la quinazolinaInfo
- Publication number
- PA8603801A1 PA8603801A1 PA20048603801A PA8603801A PA8603801A1 PA 8603801 A1 PA8603801 A1 PA 8603801A1 PA 20048603801 A PA20048603801 A PA 20048603801A PA 8603801 A PA8603801 A PA 8603801A PA 8603801 A1 PA8603801 A1 PA 8603801A1
- Authority
- PA
- Panama
- Prior art keywords
- rent
- alquil
- represents hydrogen
- amino
- replaced
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/93—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
Abstract
LA PRESENTE INVENCION SE REFIERE A LOS COMPUESTOS DE FORMULA (I) LAS FORMAS N-OXIDOS, LAS SALES DE ADICION ACEPTABLES PARA USO FARMACEUTICO Y LAS FORMAS ESTEREOQUIMICAMENTE ISOMERAS DE LOS MISMOS, DONDE: Z REPRESENTA NH; Y REPRESENTA -ALQUILO C3-C9-, -ALQUENILO C2-C9, -ALQUIL-C3-C7-CO-NH- SUSTITUIDO EN FORMA OPTATIVA CON AMINO, MONO- O DI(ALQUIL-C1-4)AMINO O ALQUILOXICARBONILAMINO C1-4-, -ALQUENIL-C3-7-CO-NH-OPCIONALMENTE SUSTITUIDO CON AMINO, MONO- O DI(ALQUIL-C1-4)AMINO O ALQUILOXICARBONILAMINO C1-4-, -ALQUIL-C1-5-NR13-ALQUILO C1-5, -ALQUIL-C1-5-NR14-CO-ALQUILO C1-5, -ALQUIL-C1-6-CO-NH-, -ALQUIL-C1-5-CO-NR15-ALQUILO C1-5-, -ALQUIL-C1-6-CO-NH-, -ALQUIL-C1-6-NH-CO-, -ALQUIL-C1-3-NH-CS-HET20-, -ALQUIL-C1-3-NH-CO-HET20-, -ALQUIL-C1-2-CO-HET21-CO-, -ALQUIL-C1-2-NH-CO-CR16R17-NH-, ALQUIL-C1-2-CO-NH-CR18R19-CO-, -ALQUIL-C1-2-CO-NR20-ALQUIL-C1-3-CO- O NR22-CO-ALQUIL-C1-3-NH-; X1 REPRESENTA UNA UNION DIRECTA, O, -O-ALQUILO C1-2-; X2 REPRESENTA UNA UNION DIRECTA, -CO-ALQUILO C1-2-,NR12,-NR12- ALQUILO C1-2-, -O-N=CH- O -ALQUILO C1-2-; R1 Y R2 CADA UNO DE FORMA IDEPENDIENTE REPRESENTA HIDROGENO O HALO; R3 REPRESENTA HIDROGENO;R4 REPRESENTA HIDROGENO O ALQUILOXI C1-4; R12 Y R13 CADA UNO DE MANERA INDEPENDIENTE REPRESENTA HIDROGENO O ALQUILO C1-4; R14 Y R15 REPRESENTAN HIDROGENO; R16 Y R17 CADA UNO DE MANERA INDEPENDIENTE REPRESENTAN HIDROGENO O ALQUILO C1-4; R18 Y R19 CADA UNO DE MANERA INDEPENDIENTE REPRESENTA HIDROGENO O ALQUILO C1-4 SUSTITUIDO DE MANERA OPCIONAL CON FENILO O HIDROXI; R20 Y R21 CADA UNO DE MANERA INDEPENDIENTE REPRESENTA HIDROGENO O ALQUILO C1-4 SUSTITUIDO DE MANERA OPCIONAL CON ALQUILOXI C1-4. HET20, HET21 Y HET22 CADA UNO EN FORMA INDEPENDIENTE REPRESENTA UN HETEROCICLO SELECCIONADO DEL GRUPO INTEGRADO POR PIRROLIDINILO, 2-PIRROLIDINONILO O PIPERIDINILO SUSTITUIDO DE MANERA OPCIONAL CON HIDROXI.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP0305723 | 2003-05-27 | ||
EP0310266 | 2003-09-15 | ||
EP0351061 | 2003-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8603801A1 true PA8603801A1 (es) | 2004-12-16 |
Family
ID=33493782
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA20048603801A PA8603801A1 (es) | 2003-05-27 | 2004-05-24 | Derivados de la quinazolina |
Country Status (32)
Country | Link |
---|---|
US (4) | US7648975B2 (es) |
EP (2) | EP2305687A1 (es) |
JP (1) | JP4887151B2 (es) |
KR (1) | KR101143878B1 (es) |
CN (1) | CN102718775B (es) |
AR (2) | AR045687A1 (es) |
AT (1) | ATE544454T1 (es) |
AU (1) | AU2004243487B2 (es) |
BR (1) | BRPI0410714B8 (es) |
CA (1) | CA2525214C (es) |
CL (1) | CL2004001267A1 (es) |
CO (1) | CO5640038A2 (es) |
CY (1) | CY1113002T1 (es) |
DK (1) | DK1633365T3 (es) |
EA (1) | EA009064B1 (es) |
ES (1) | ES2381976T3 (es) |
HK (1) | HK1176350A1 (es) |
HR (1) | HRP20120351T1 (es) |
IL (3) | IL172154A0 (es) |
IS (1) | IS3030B (es) |
JO (1) | JO2785B1 (es) |
MX (1) | MXPA05012762A (es) |
MY (1) | MY148633A (es) |
NO (1) | NO334209B1 (es) |
NZ (1) | NZ544154A (es) |
PA (1) | PA8603801A1 (es) |
PL (1) | PL1633365T3 (es) |
PT (1) | PT1633365E (es) |
SI (1) | SI1633365T1 (es) |
TW (3) | TWI468397B (es) |
UA (1) | UA84010C2 (es) |
WO (1) | WO2004105765A1 (es) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO2785B1 (en) * | 2003-05-27 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | Quinazoline derivatives |
EP1684762A4 (en) * | 2003-11-13 | 2009-06-17 | Ambit Biosciences Corp | UREA DERIVATIVES AS MODULATORS OF KINASE |
NZ547795A (en) | 2003-12-18 | 2009-07-31 | Janssen Pharmaceutica Nv | 3-Cyano-quinoline derivatives with antiproliferative activity |
MXPA06007017A (es) | 2003-12-18 | 2006-08-31 | Janssen Pharmaceutica Nv | Derivados de pirido y pirimidopirimidina como agentes antiproliferativos. |
MY169441A (en) | 2004-12-08 | 2019-04-11 | Janssen Pharmaceutica Nv | 2,4, (4,6) pyrimidine derivatives |
JO3088B1 (ar) * | 2004-12-08 | 2017-03-15 | Janssen Pharmaceutica Nv | مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف |
NI200700147A (es) | 2004-12-08 | 2019-05-10 | Janssen Pharmaceutica Nv | Derivados de quinazolina inhibidores de cinasas dirigidos a multip |
KR100910333B1 (ko) | 2005-02-23 | 2009-07-31 | 시오노기세이야쿠가부시키가이샤 | 타이로신 키나아제 억제 활성을 갖는 퀴나졸린 유도체 |
GB0509227D0 (en) * | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
CA2611438C (en) * | 2005-06-30 | 2014-01-07 | Janssen Pharmaceutica N.V. | Cyclic anilino-pyridinotriazines |
MX2009000456A (es) * | 2006-07-13 | 2009-01-27 | Janssen Pharmaceutica Nv | Derivados de quinazolina mtki. |
JP2009242240A (ja) * | 2006-08-04 | 2009-10-22 | Mebiopharm Co Ltd | 含ホウ素キナゾリン誘導体 |
US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
MX2009002585A (es) | 2006-09-11 | 2009-08-24 | Curis Inc | Inhibidores e egfr a base de quinolina que contienen porcion de enlace de zinc. |
WO2008033748A2 (en) * | 2006-09-11 | 2008-03-20 | Curis, Inc. | Quinazoline based egfr inhibitors containing a zinc binding moiety |
EA200970420A1 (ru) * | 2006-10-27 | 2009-12-30 | Янссен Фармацевтика Нв | Применение mtki 1 для лечения или предупреждения рака кости |
EP2402752A3 (en) * | 2006-10-27 | 2012-06-06 | Janssen Pharmaceutica, N.V. | A method for pharmacologically profiling compounds |
KR20090091119A (ko) * | 2006-10-27 | 2009-08-26 | 얀센 파마슈티카 엔.브이. | 뇌암을 치료하거나 예방하기 위한 mt 키나아제 저해제의 용도 |
KR20090089849A (ko) * | 2006-10-27 | 2009-08-24 | 얀센 파마슈티카 엔.브이. | Vegfr3 저해제로서의 마크로사이클릭 퀴나졸린 유도체 |
EP2123627B1 (en) * | 2007-01-19 | 2013-11-20 | Ube Industries, Ltd. | Process for producing aromatic amine having aralkyloxy or heteroaralkyloxy group |
US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
ES2562218T3 (es) | 2007-07-27 | 2016-03-03 | Janssen Pharmaceutica, N.V. | Pirrolopirimidinas útiles para el tratamiento de enfermedades proliferativas |
US8119616B2 (en) | 2007-09-10 | 2012-02-21 | Curis, Inc. | Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety |
CL2008003384A1 (es) * | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
US8426430B2 (en) | 2008-06-30 | 2013-04-23 | Hutchison Medipharma Enterprises Limited | Quinazoline derivatives |
US8450322B2 (en) | 2008-09-22 | 2013-05-28 | Array Biopharma Inc. | Substituted imidazo[1,2b]pyridazine compounds as Trk kinase inhibitors |
EP3372605B1 (en) | 2008-10-22 | 2021-11-03 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors |
WO2010085597A1 (en) * | 2009-01-23 | 2010-07-29 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
TWI406853B (zh) * | 2010-04-07 | 2013-09-01 | Dev Center Biotechnology | Egfr與vegfr-2雙重抑制劑及其用途與製法 |
RU2594742C2 (ru) | 2010-05-20 | 2016-08-20 | Эррэй Биофарма Инк. | Макроциклические соединения в качестве ингибиторов киназы trk |
WO2013126015A1 (en) | 2012-02-23 | 2013-08-29 | N. V. Nutricia | Composition comprising non- digestible oligosaccharides |
PL2822953T3 (pl) * | 2012-03-06 | 2017-07-31 | Pfizer Inc. | Makrocykliczne pochodne do leczenia chorób proliferacyjnych |
CN104513253A (zh) * | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | 用于治疗增殖性疾病的大环化合物 |
EP4309653A1 (en) * | 2014-02-07 | 2024-01-24 | Exithera Pharmaceuticals Inc. | Therapeutic compounds and compositions |
MA39822A (fr) | 2014-04-03 | 2018-02-06 | Janssen Pharmaceutica Nv | Dérivés de pyrimidine bicycle |
MA39823A (fr) | 2014-04-03 | 2018-01-09 | Janssen Pharmaceutica Nv | Dérivés de pyridine macrocyclique |
LT3699181T (lt) | 2014-11-16 | 2023-05-10 | Array Biopharma, Inc. | Kristalinė (s)-n-(5-((r)-2-(2,5-difluorfenil)-pirolidin-1-il)-pirazolo[1,5-a] pirimidin-3-il)-3 -hidroksipirolidino-1-karboksamido vandenilio sulfato forma |
BR112018006873A2 (pt) | 2015-10-05 | 2018-11-06 | The Trustees Of Columbia University In The City Of New York | ativadores do fluxo autofágico e fosfolipase d e depuração de agregados de proteína incluindo tau e tratamento de proteinopatias |
TN2019000271A1 (en) | 2015-10-26 | 2021-01-07 | Univ Colorado Regents | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
EP3423113B1 (en) * | 2016-02-29 | 2020-09-02 | Oncodesign S.A. | Radiolabeled macrocyclic egfr inhibitor |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
MA44610A (fr) | 2016-04-04 | 2019-02-13 | Loxo Oncology Inc | Formulations liquides de (s)-n-(5-((r)-2-(2,5-difluorophényl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
HUE053643T2 (hu) | 2016-05-18 | 2021-07-28 | Loxo Oncology Inc | (S)-N-(5 -((R)-2-(2,5-difluor-fenil)-pirrolidin-1-il)-pirazolo[1,5-A] pirimidin-3-il)-3-hidroxi-pirrolidin-1-karboxamid elõkészítése |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
MA51052A (fr) * | 2017-12-07 | 2021-04-21 | Amplyx Pharmaceuticals Inc | Agents antifongiques dérivés de pyridine substitués par un hétérocycle |
CA3104653A1 (en) | 2018-06-25 | 2020-01-02 | Amplyx Pharmaceuticals, Inc. | Pyridine derivatives substituted by heterocyclic ring and amino group |
US20230159556A1 (en) * | 2020-04-20 | 2023-05-25 | Tenova Pharmaceuticals Inc. | Novel protein kinase inhibitors |
TW202333709A (zh) | 2021-12-16 | 2023-09-01 | 美商奇奈特生物製藥公司 | Met激酶抑制劑 |
WO2024017258A1 (zh) * | 2022-07-19 | 2024-01-25 | 百极弘烨(南通)医药科技有限公司 | Egfr小分子抑制剂、含其的药物组合物及其用途 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE558251A (es) * | 1956-06-11 | |||
DE2423536A1 (de) * | 1974-05-15 | 1975-11-27 | Bayer Ag | 3-amino-phenylessigsaeure-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide |
US4066772A (en) * | 1975-07-21 | 1978-01-03 | Janssen Pharmaceutica N.V. | 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds |
NZ181256A (en) * | 1975-07-21 | 1978-04-28 | Janssen Pharmaceutica Nv | 1-(w-benzazol-11-ylalkyl)-piperidine derivatives and pharmaceutical compositions containing certain of these derivatives |
US4126687A (en) | 1976-05-17 | 1978-11-21 | Janssen Pharmaceutica N.V. | Antiemetic, 1-(benzimidazolyl-alkyl)-piperidine derivatives |
US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
GB9510757D0 (en) * | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
CN100503580C (zh) * | 1996-04-12 | 2009-06-24 | 沃尼尔·朗伯公司 | 酪氨酸激酶的不可逆抑制剂 |
GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
PT1117653E (pt) | 1998-10-01 | 2003-06-30 | Astrazeneca Ab | Derivados de quinolina e quinazolina e sua utilizacao como inibidores de doencas mediadas pela citosina |
FR2809400B1 (fr) * | 2000-05-25 | 2004-04-09 | Inst Francais Du Petrole | Materiaux comportant des groupements organiques contenant du soufre et du phosphore lie par l'intermediaire d'atomes d'oxygenes a un oxyde mineral |
JO2785B1 (en) * | 2003-05-27 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | Quinazoline derivatives |
JO3088B1 (ar) * | 2004-12-08 | 2017-03-15 | Janssen Pharmaceutica Nv | مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف |
GB2446974B (en) * | 2006-04-13 | 2009-01-14 | Siemens Magnet Technology Ltd | A solenoidal magnet structure |
-
2004
- 2004-05-24 JO JO200466A patent/JO2785B1/en active
- 2004-05-24 PA PA20048603801A patent/PA8603801A1/es unknown
- 2004-05-25 JP JP2006529915A patent/JP4887151B2/ja active Active
- 2004-05-25 CL CL200401267A patent/CL2004001267A1/es unknown
- 2004-05-25 CN CN201210144221.7A patent/CN102718775B/zh active Active
- 2004-05-25 KR KR1020057022189A patent/KR101143878B1/ko active IP Right Grant
- 2004-05-25 AU AU2004243487A patent/AU2004243487B2/en active Active
- 2004-05-25 AT AT04739341T patent/ATE544454T1/de active
- 2004-05-25 MY MYPI20042004A patent/MY148633A/en unknown
- 2004-05-25 CA CA2525214A patent/CA2525214C/en active Active
- 2004-05-25 NZ NZ544154A patent/NZ544154A/en unknown
- 2004-05-25 DK DK04739341.8T patent/DK1633365T3/da active
- 2004-05-25 EP EP10192741A patent/EP2305687A1/en not_active Withdrawn
- 2004-05-25 US US10/558,007 patent/US7648975B2/en active Active
- 2004-05-25 PT PT04739341T patent/PT1633365E/pt unknown
- 2004-05-25 EP EP04739341A patent/EP1633365B1/en active Active
- 2004-05-25 WO PCT/EP2004/005621 patent/WO2004105765A1/en active Application Filing
- 2004-05-25 PL PL04739341T patent/PL1633365T3/pl unknown
- 2004-05-25 EA EA200501866A patent/EA009064B1/ru unknown
- 2004-05-25 SI SI200431864T patent/SI1633365T1/sl unknown
- 2004-05-25 BR BRPI0410714A patent/BRPI0410714B8/pt not_active Application Discontinuation
- 2004-05-25 MX MXPA05012762A patent/MXPA05012762A/es active IP Right Grant
- 2004-05-25 ES ES04739341T patent/ES2381976T3/es active Active
- 2004-05-25 UA UAA200510181A patent/UA84010C2/ru unknown
- 2004-05-26 TW TW101115205A patent/TWI468397B/zh active
- 2004-05-26 TW TW101115204A patent/TWI468372B/zh active
- 2004-05-26 TW TW093114851A patent/TWI379835B/zh active
- 2004-05-26 AR ARP040101806A patent/AR045687A1/es active IP Right Grant
-
2005
- 2005-10-14 IS IS8077A patent/IS3030B/is unknown
- 2005-11-24 CO CO05119403A patent/CO5640038A2/es active IP Right Grant
- 2005-11-24 IL IL172154A patent/IL172154A0/en active IP Right Grant
- 2005-12-27 NO NO20056196A patent/NO334209B1/no unknown
-
2009
- 2009-11-24 US US12/624,637 patent/US8394786B2/en active Active
-
2012
- 2012-04-19 HR HRP20120351TT patent/HRP20120351T1/hr unknown
- 2012-05-08 CY CY20121100428T patent/CY1113002T1/el unknown
-
2013
- 2013-01-18 US US13/744,878 patent/US9273013B2/en active Active
- 2013-03-12 HK HK13103104.2A patent/HK1176350A1/zh unknown
- 2013-08-15 AR ARP130102897A patent/AR092137A2/es unknown
-
2014
- 2014-06-10 IL IL233045A patent/IL233045B/en active IP Right Grant
- 2014-06-10 IL IL233046A patent/IL233046A0/en active IP Right Grant
-
2016
- 2016-01-21 US US15/003,124 patent/US20160207938A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8603801A1 (es) | Derivados de la quinazolina | |
UY27226A1 (es) | Pirazolopirimidinas como agentes terapéuticos | |
ECSP034773A (es) | Pirazolopirimmidinas como agentes terapeuticos | |
CR8744A (es) | Compuestos terapeuticos | |
ECSP088246A (es) | Nuevos derivados de benzotiazolona | |
BRPI0608886B8 (pt) | derivados de n-sulfonilpirróis e seus usos | |
DE60328010D1 (de) | Heterocyclische verbindungen | |
CO7141456A2 (es) | Derivados de aril-sultamo como moduladores de rorc | |
AR055613A1 (es) | Formas cristalinas delta y epsilon de mesilato de imatinib | |
ECSP105253A (es) | Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa | |
UY29384A1 (es) | Derivados del ácido2-3s,4r)-4-(((3,4-dicloro-5-metil-1h-pirrol-2-il) carbonil)amino)-1,3-tiazol-5-carboxílico y sus sales, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciónes. | |
BR0214891A (pt) | Herbicidas | |
BR0211805A (pt) | Herbicidas | |
UY29705A1 (es) | " inhibidores macrocíclicos del virus de la hepatitis c" | |
UY30274A1 (es) | Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones | |
UY28671A1 (es) | Pirido(2.3-d)pirimidina-2,4-diaminas como inhibidores de pde 2 | |
AR053554A1 (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
CR8216A (es) | Formula liquida para la proteccion de las plantas | |
UY29844A1 (es) | Formulación en aerosol para la inhalación de beta-agonistas | |
CR7956A (es) | Oxazolidinonas de indolona antibacterial intermedios para su preparacion y composiciones farmaceuticas que contienen los mismos | |
CY1109883T1 (el) | Υδατικα συγκεντρωματα δραστικων ουσιων με ζιζανιοκτονα δραση | |
ES2421948T3 (es) | Compuestos y composiciones para suministrar agentes activos | |
AR056860A1 (es) | Derivados de triazol inhibidores de receptores de quinasa tgf-beta1, composiciones farmaceuticas que los contienen y usos para el tratamiento de tumores | |
PA8485101A1 (es) | Nuevos antibioticos macrolidos. | |
AR074604A1 (es) | Derivados de 5-amino-2-(1-hidroxi-etil)-tetrahidropirano. |